Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.
Pershing Square and Valeant were accused of improper trading ahead of 2014 bid for Botox maker
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.
Администрация президента США празднует налоговую победу. Хедж-фондам тоже стоило бы, хотя они могут лишиться возможности налогового маневра
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.
Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.
Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA
Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.
В этом году бумаги американских компаний, торгующиеся в России, попали в топ самых ликвидных акций на местном рынке. С чем это связано и как вложиться в акции из S&P 500 в рамках российского законодательства